Arnarlax Ehf, Has Finalized Sustainable Linked Facility Agreement With a New EUR 100 Million Bank Facility
Arnarlax ehf., a wholly-owned subsidiary of Icelandic Salmon AS, successfully signed a Sustainable Linked Facility agreement aimed at refinancing existing loan facilities. The new facility will support the company's growth strategy and enhance operational flexibility.
"We have secured a EUR 100 million sustainable linked credit facility, with a three-year tenor, through a good collaborative effort with DNB, Danske Bank, and Arion Bank" say Jónas Heiðar Birgisson, CFO and continues "Having a Sustainable Linked financing with favourable competitive terms support the company's vision and ambition to be Icelandic Sustainable fish farmer. We are happy to continue our collaboration with DNB and Arion Bank and we look forward working with Danske bank as a strong addition to our team".
The facility encompasses a term loan facility, a revolving facility, and an overdraft facility, complete with the added flexibility of two one-year extension options. The new financing agreement is fully finalized and is not subjected to any other documentations.
For further information, please contact:
CEO Bjørn Hembre
Tel: +354 620 1936
CFO Jónas Heiðar Birgisson
Tel: +354 414 0609
About Icelandic Salmon:
Icelandic Salmon is listed at the Euronext Growth. The company is the 100% owner of Arnarlax ehf, the leading farming company in Iceland with their head office in Bildudalur. The company is fully integrated, from egg to the fish is delivered to customers in the market, with control over all parts of the value chain. See https://www.arnarlax.is for more information about the company.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Resultat af auktion over skatkammerbeviser 29. november 202329.11.2023 10:25:38 CET | pressemeddelelse
Bud, salg, skæringsrenter og pris fremgår af nedenstående oversigt: ISINBud mio. kr. (nominelt)SalgSkæringsrente (pct.)Pro-rataKurs98 19237 SKBV 24 / I1.220 960 3,500 100 %99,1230 98 19310 SKBV 24 / II1.760 1.020 3,450 100 %98,2580 I alt2.980 1.980 Salget bliver afviklet den 1. december 2023
Result of the auction of treasury bills on 29 November 202329.11.2023 10:25:38 CET | Press release
Bids, sales, stop-rates and prices are presented in the table below: ISINBid Mill. kr. (nominal)SaleStop-rate (per cent)Pro-rataPrice98 19237 DKT 01/03/24 I1,220960 3.500 100 %99.1230 98 19310 DKT 03/06/24 II1,760 1,020 3.450 100 %98.2580 Total2,980 1,980 The sale will settle 1 December 2023
Dassault Aviation Wins Choiseul “Strategic Company” Award29.11.2023 10:21:57 CET | Press release
Dassault Aviation Wins Choiseul “Strategic Company” Award (Saint-Cloud, November 29, 2023) – Dassault Aviation is particularly proud to have received the 2023 Strategic Company Award as part of the Institut Choiseul’s Sovereignty Initiative. The institute believes that strategic companies represent one of the many facets of national strength. Award recipients are known for their capacity to effectively mobilize resources and know-how, and to provide solutions that meet national priorities. They are a cornerstone of French strategic heritage. Dassault Aviation is an industrial architect and complex systems integrator, a developer of strategic technologies, a major national exporter, a core shareholder of the Thales Group and a vital player in an industrial landscape that includes hundreds of business and service partners. The company is at the core of the French sovereign defense ecosystem. Dassault Aviation is also the only non-American company that manufactures high-end business jets.
Company announcement no 17/2023 Interim Report Q3 202329.11.2023 10:20:00 CET | Press release
Interim Report Q3 2023 EBITDA fixed herd prices (FHP) for Q3 2023 increased to 13.663 mEUR (Q3 2022: 10.463 kEUR), corresponding to an EBITDA margin FHP of 36.3% (Q3 2022: 32.5%). The quarterly EBITDA in Q3 2023 increased by 3.201 kEUR (compared to Q3 2022). Nevertheless, this consist of many parts this quarter: Russia harvest negative with 2,7 mEUR (from 4,1 to 1,5 mEUR) whereas remaining Russian business compensate positive with 3,0 mEUR partly due to FX (cost in EUR lower), Lithuania negative effects from one-off subsidy in Q3 2022 (2,5 mEUR), but combined sales/feed with positive effect of 4.9 mEUR and lower cost levels with 0.5 mEUR driven by utilities. Sales prices combined down, as they in Q3 2023 were 1.59 EUR/kg live weight, down from 1.62 EUR/kg Q2 2022 equal to EUR 0,8m, but EURRUB effects this picture highly as Lithuanian sales prices in EUR is up 23% and Russian in RUB is up 13%. Feed prices in Q3 2023 were 261 EUR/T (compared to 332 EUR/T Q3 2022). End September 2023 on h
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®29.11.2023 10:00:00 CET | Press release
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study, which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects, met its primary endpoints. “These results demonstrate the strength of our platform approach to biosimilars development and manufacture, combining a well-designed and executed clinical study with the design of a high-quality manufacturing process and strong analytical capabilities,” said Joseph McClellan, Chief Scientific Officer. “As we progress more biosimilar candidates through clinical development and approval, w